Recent Publications

Keyel ME, Furr KL, Kang MH, Reynolds CP: A multi-color flow cytometric assay for quantifying dinutuximab binding to neuroblastoma cells in tumor, bone marrow, and blood. J Clinical Medicine 12(19) 6223, 2023.
Mani C, Ganesh A, Saamarthy K, Ochola D, Mereddy S, Pruitt K, Manne U and Palle K. (2023) Racial differences in RAD51 expression is regulated by miRNA-214-5P and its inhibition synergizes with olaparib in triple-negative breast cancer. Breast Cancer Research. 25 (1): 44. PMID: 37081516; PMCID: PMC10120249.
Tyler Sniegowski, Devaraja Rajasekaran, Souad R Sennoune, Sukumaran Sunitha, Fang Chen, Mohamed Fokar, Sudhir Kshirsagar, P Hemachandra Reddy, Ksenija Korac, Mosharaf Mahmud Syed, Tanima Sharker, Vadivel Ganapathy, Yangzom D Bhutia. (2023) Amino acid transporter SLC38A5 is a tumor promoter and a novel therapeutic target for pancreatic cancer. Scientific Reports 6:13(1):16863 PMID: 347803043
SJ Wei, IH Yang, IS Mohiuddin, GJ Kshirsagar, TH Nguyen, S Trasti, BJ Maurer, MH Kang (2023) DNA-PKcs as an upstream mediator of OCT4-induced MYC activation in small cell lung cancer. Biochim Biophys Acta Gene Regul Mech. Jun;1866(2):194939, PMID: 37116859

Babcock RL, Pruitt K. Letting go: Dishevelled phase separation recruits Axin to stabilize β-catenin. J Cell Biol. Dec 5 2022;221(12)
Bhutia YD, Mathew M, Sivaprakasam S, Ramachandran S, Ganapathy V. Unconventional Functions of Amino Acid Transporters: Role in Macropinocytosis (SLC38A5/SLC38A3) and Diet-Induced Obesity/Metabolic Syndrome (SLC6A19/SLC6A14/SLC6A6). Biomolecules. Jan 31 2022;12(2)
Blanton HL, McHann MC, De Selle H, Dancel CL, Redondo JL, Molehin D, German NA, Trasti S, Pruitt K, Castro-Piedras I, Guindon J. Chronic Administration of Cannabinoid Receptor 2 Agonist (JWH-133) Increases Ectopic Ovarian Tumor Growth and Endocannabinoids (Anandamide and 2-Arachidonoyl Glycerol) Levels in Immunocompromised SCID Female Mice. Front Pharmacol. 2022;13;823132.
Boligala GP, Yang MV, van Wunnik JC, Pruitt K. Nuclear Dishevelled: An enigmatic role in governing cell fate and Wnt signaling. Biochim Biophys Acta Mol Cell Res. Oct 2022;1869(10);119305.
Calderón-Mora J, Alomari A, Byrd TL, Shokar NK. Evaluation of a Narrative Video to Promote Prevention and Early Detection of Cervical Cancer Among Latinas. Health Promot Pract. Sep 2022;23(5);884-891.
Chen Z, Xia X, Chen H, Huang H, An X, Sun M, Yao Q, Kim K, Zhang H, Chu M, Chen R, Bhutia YD, Ganapathy V, Kou L. Carbidopa suppresses estrogen receptor-positive breast cancer via AhR-mediated proteasomal degradation of ERα. Invest New Drugs. Dec 2022;40(6);1216-1230.
Chyu J, Ali Z, Al-Rahawan MM. Comments on evaluation of an oral sodium bicarbonate protocol for high-dose methotrexate urine alkalinization. Support Care Cancer. Dec 2022;30(12);9699-9700.
Çoku J, Booth DM, Skoda J, Pedrotty MC, Vogel J, Liu K, Vu A, Carpenter EL, Ye JC, Chen MA, Dunbar P, Scadden E, Yun TD, Nakamaru-Ogiso E, Area-Gomez E, Li Y, Goldsmith KC, Reynolds CP, Hajnoczky G, Hogarty MD. Reduced ER-mitochondria connectivity promotes neuroblastoma multidrug resistance. Embo j. Apr 19 2022;41(8);e108272.
Evans NJ, Schneider AC, Castro-Piedras I, Oliver AG, Mabry AB, Garcia AK, Velez-Colon MDC, Nichols J, Grisham MB, Pruitt K, Suarez-Martinez EB, Almodovar S. SARS-CoV-2 and HIV: Impact on Pulmonary Epithelial Cells. Life (Basel). Aug 26 2022;12(9)
Ghafouri SR, Guvvala S, Jones C, Philipovskiy A. Recently approved treatment options for patients with metastatic triple-negative and HER2-neu-positive breast cancer. J Investig Med. Aug 2022;70(6);1329-1341.
Hindle A, Bose C, Lee J, Palade PT, Peterson CJ, Reddy PH, Awasthi S, Singh SP. Rlip Depletion Alters Oncogene Transcription at Multiple Distinct Regulatory Levels. Cancers (Basel). Jan 21 2022;14(3)
Khan SY, Melkus MW, Rasha F, Castro M, Chu V, Brandi L, Khan H, Gill HS, Pruitt K, Layeequr Rahman R. Tumor-Infiltrating Lymphocytes (TILs) as a Biomarker of Abscopal Effect of Cryoablation in Breast Cancer: A Pilot Study. Ann Surg Oncol. May 2022;29(5);2914-292
Korac K, Rajasekaran D, Sniegowski T, Schniers BK, Ibrahim AF, Bhutia YD. Carbidopa, an activator of aryl hydrocarbon receptor, suppresses IDO1 expression in pancreatic cancer and decreases tumor growth. Biochem J. Sep 16 2022;479(17);1807-1824.
Lee S, Maegawa FB, Joseph S, Alvarado LA, Mendoza-Ladd A, Elhanafi S, Philipovskiy A, Tyroch AH, Konstantinidis IT. Pancreatic Neuroendocrine Tumors: The Effect of Facility Type on Patient Survival. Pancreas. Mar 1 2022;51(3);282-287.
Macha SJ, Koneru B, Burrow TA, Zhu C, Savitski D, Rahman RL, Ronaghan CA, Nance J, McCoy K, Eslinger C, Reynolds CP. Alternative Lengthening of Telomeres in Cancer Confers a Vulnerability to Reactivation of p53 Function. Cancer Res. Sep 16 2022;82(18);3345-3358.
Maegawa FB, Ahmad M, Aguirre K, Elhanafi S, Chiba S, Philipovskiy A, Tyroch AH, Konstantinidis IT. The impact of minimally invasive surgery and frailty on post-hepatectomy outcomes. HPB (Oxford). Sep 2022;24(9);1577-1584.
Mani C, Acharya G, Kshirsagar S, Vijayan M, Khan H, Reddy PH, Palle K. A Novel Role for BRIP1/FANCJ in Neuronal Cells Health and in Resolving Oxidative Stress-Induced DNA Lesions. J Alzheimers Dis. 2022;85(1);207-221.
Mani C, Tripathi K, Omy TR, Reedy M, Manne U, Palle K. GLI1-targeting drugs induce replication stress and homologous recombination deficiency and synergize with PARP-targeted therapies in triple negative breast cancer cells. Biochim Biophys Acta Mol Basis Dis. Feb 1 2022;1868(2);166300.
Manna PR, Ahmed AU, Molehin D, Narasimhan M, Pruitt K, Reddy PH. Hormonal and Genetic Regulatory Events in Breast Cancer and Its Therapeutics: Importance of the Steroidogenic Acute Regulatory Protein. Biomedicines. Jun 3 2022;10(6)
Masoumzadeh E, Grozdanov PN, Jetly A, MacDonald CC, Latham MP. Electrostatic Interactions between CSTF2 and pre-mRNA Drive Cleavage and Polyadenylation. Biophys J. Feb 15 2022;121(4);607-619.
Menikdiwela KR, Kahathuduwa C, Bolner ML, Rahman RL, Moustaid-Moussa N. Association between Obesity, Race or Ethnicity, and Luminal Subtypes of Breast Cancer. Biomedicines. Nov 15 2022;10(11)
Ogura J, Sato T, Higuchi K, Sivaprakasam S, Kopel J, Bhutia YD, Ganapathy V. Binding of Citrate-Fe(3+) to Plastic Culture Dishes, an Artefact Useful as a Simple Technique to Screen for New Iron Chelators. Int J Mol Sci. Jun 15 2022;23(12)
Parmar K, Benjanuwattra J, Sethi P, Tijani L, Hurst P, Pertuz GD, Argueta-Sosa E. Cardiac amyloidosis-An underdiagnosed cause of heart failure: A case report and review of literature. Clin Case Rep. Dec 2022;10(12);e6525.
Pawar D, Arif D, Raghunath A, Rehman S. Urothelial carcinoma with mandibular metastasis and synchronous prostate cancer. BMJ Case Rep. Mar 14 2022;15(3)
Rahman RL. Wisdom is in the eye of the beholder. Am J Surg. Jul 2022;224(1 Pt A);6-7.
Rodriguez-Irizarry VJ, Schneider AC, Ahle D, Smith JM, Suarez-Martinez EB, Salazar EA, McDaniel Mims B, Rasha F, Moussa H, Moustaïd-Moussa N, Pruitt K, Fonseca M, Henriquez M, Clauss MA, Grisham MB, Almodovar S. Mice with humanized immune system as novel models to study HIV-associated pulmonary hypertension. Front Immunol. 2022;13;936164.
Schniers BK, Wachtel MS, Sharma M, Korac K, Rajasekaran D, Yang S, Sniegowski T, Ganapathy V, Bhutia YD. Deletion of Slc6a14 reduces cancer growth and metastatic spread and improves survival in KPC mouse model of spontaneous pancreatic cancer. Biochem J. Mar 18 2022;479(5);719-730.
Stachelek K, Harutyunyan N, Lee S, Beck A, Kim J, Xu L, Berry JL, Nagiel A, Reynolds CP, Murphree AL, Lee TC, Aparicio JG, Cobrinik D. Non-synonymous, synonymous, and non-coding nucleotide variants contribute to recurrently altered biological processes during retinoblastoma progression. Genes Chromosomes Cancer. Dec 22 2022.
Whitworth P, Beitsch PD, Pellicane JV, Baron PL, Lee LA, Dul CL, Nash CH, 3rd, Murray MK, Richards PD, Gittleman M, Budway R, Rahman RL, Kelemen P, Dooley WC, Rock DT, Cowan K, Lesnikoski BA, Barone JL, Ashikari AY, Dupree B, Wang S, Menicucci AR, Yoder EB, Finn C, Corcoran K, Blumencranz LE, Audeh W. Age-Independent Preoperative Chemosensitivity and 5-Year Outcome Determined by Combined 70- and 80-Gene Signature in a Prospective Trial in Early-Stage Breast Cancer. Ann Surg Oncol. Apr 4 2022;29(7);4141-52.
Whitworth PW, Beitsch PD, Murray MK, Richards PD, Mislowsky A, Dul CL, Pellicane JV, Baron PL, Rahman RL, Lee LA, Dupree BB, Kelemen PR, Ashikari AY, Budway RJ, Lopez-Penalver C, Dooley W, Wang S, Dauer P, Menicucci AR, Yoder EB, Finn C, Blumencranz LE, Audeh W. Genomic Classification of HER2-Positive Patients With 80-Gene and 70-Gene Signatures Identifies Diversity in Clinical Outcomes With HER2-Targeted Neoadjuvant Therapy. JCO Precis Oncol. Sep 2022;6;e2200197.
Whitworth PW, Beitsch PD, Pellicane JV, Baron PL, Lee LA, Dul CL, Murray MK, Gittleman MA, Budway RJ, Rahman RL, Kelemen PR, Dooley WC, Rock DT, Cowan KH, Lesnikoski BA, Barone JL, Ashikari AY, Dupree BB, Wang S, Menicucci AR, Yoder EB, Finn C, Corcoran K, Blumencranz LE, Audeh W. Distinct Neoadjuvant Chemotherapy Response and 5-Year Outcome in Patients With Estrogen Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative Breast Tumors That Reclassify as Basal-Type by the 80-Gene Signature. JCO Precis Oncol. Apr 2022;6(1);e2100463.

Koneru B, Farooqi A, Nguyen TH, Chen WH, Hindle A, Eslinger C, Makena MR, Burrow TA, Wilson J, Smith A, Reddy VP, Cadogan E, Durant ST, Reynolds CP: ALT neuroblastoma chemoresistance due to ATM-dependent telomere dysfunction is reversible with the ATM inhibitor AZD015. Science Translational Medicine In Revision, 2021. Go to Publication
Hindle, A, Koneru B, Makena MR, Nguyen TH, Chen WH, Reynolds CP: MGMT inhibitor O6-benzylguanine enhanced temozolomide + irinotecan activity against in vitro and in vivo models of progressive disease high-risk neuroblastoma. Anticancer Drugs 32:233-247, 2021. PMID: 33323683

Koneru B, Lopez G, Farooqi A, Conkrite KL, Nguyen TH, Macha S, Modi A, Rokita JL, Urias E , Hindle A, Davidson H , Mccoy K, Nance J, Yezdani V, Shengping S, Wheeler DA , Maris JM, Diskin SJ, Reynolds CP: Telomere maintenance mechanisms define clinical outcome in high-risk neuroblastoma. Cancer Research 80:2663-75, 2020. PMID: 32291317

Song MM, Makena MR, Hindle A, Koneru B, Nguyen TH, Verlekar DU, Cho H, Maurer BJ, Kang MH, Reynolds CP:. Cytotoxicity and molecular activity of fenretinide and metabolites in T-cell lymphoid malignancy, neuroblastoma, and ovarian cancer cell lines in physiological hypoxia. Anti-Cancer Drugs 30:117-127, 2019 PMID: 30272587.
Keyel ME and Reynolds CP: Spotlight on dinutuximab in the treatment of high-risk neuroblastoma: development and place in therapy. Biologics: Targets and Therapy 13:1-12, 2019. PMID: 30613134
Lowery CD, Dowless M, Renschler M, Blosser W, VanWye AB, Stephens JR, Iversen PW, Bence Lin A, R PB, Krytska K, Cole KA, Maris JM, Hawkins DS, Rubin BP, Kurmasheva RT, Houghton PJ, Gorlick R, Kolb EA, Kang MH, Reynolds CP, Erickson SW, Teicher BA, Smith MA, Stancato LF: Broad spectrum activity of the checkpoint kinase 1 inhibitor prexasertib as a single agent or chemopotentiator across a range of preclinical pediatric tumor models. Clinical Cancer Research 2018. PMID: 30563935
Nguyen TH, Koneru B, Wei S, Chen WJ, Makena MR, Urias E, Kang MH, Reynolds CP: Fenretinide via NOXA induction, enhanced activity of the BCL-2 inhibitor venetoclax in high BCL-2-expressing neuroblastoma preclinical models. Molecular Cancer Therapeutics doi 1143/1537-7163.MCT-19-0385, 2019. PMID: 31484706
Trigg RM, Lee LC, Prokoph N, Jahangiri L, Reynolds CP, Amos Burke GA, Probst NA, Han M, Matthews JD, Kai Lim H, Manners E, Martinez S, Pastor J, Blanco-Aparicio C, Merkel O, de Los Fayos Alonso IG, Kodajova P, Tangermann S, Högler S, Luo J, Kenner L, Turner SD. The targetable kinase PIM1 drives ALK inhibitor resistance in high-risk neuroblastoma independent of MYCN status. Nature Commun. 10:5428, 2019. PMID: 31780656

Al-Rahawan MG, Trevino S, Jacob R, Murray JC, Al-Rahawan MM. Medulloblastoma in a toddler with Gorlin syndrome. Proceedings (Baylor University Medical Center) 2018;31(2):216-8 doi 10.1080/08998280.2018.1435111.
Awasthi S, Tompkins J, Singhal J, Riggs AD, Yadav S, Wu X, et al. Rlip depletion prevents spontaneous neoplasia in TP53 null mice. Proceedings of the National Academy of Sciences of the United States of America 2018;115(15):3918-23 doi 10.1073/pnas.1719586115.
Bhatt B, Zeng P, Zhu H, Sivaprakasam S, Li S, Xiao H, et al. Gpr109a Limits Microbiota-Induced IL-23 Production To Constrain ILC3-Mediated Colonic Inflammation. Journal of immunology (Baltimore, Md : 1950) 2018;200(8):2905-14 doi 10.4049/jimmunol.1701625.
Camacho J, Grand R, Blevins N, Sharma P, de Riese W, Cammack J. Occlusion of bilateral dorsal penile arteries resulting in glans necrosis in an obese male truck driver. Radiology case reports 2018;13(2):397-9 doi 10.1016/j.radcr.2018.01.021.
Chipollini J, Tang DH, Sharma P, Spiess PE. National Trends and Predictors of Organ-sparing for Invasive Penile Tumors: Expanding the Therapeutic Window. Clinical Genitourinary Cancer 2018;16(2):e383-e9 doi 10.1016/j.clgc.2017.09.004.
Cho HE, Kang MH. pH gradient-liquid chromatography tandem mass spectrometric assay for determination of underivatized polyamines in cancer cells. Journal of Chromatography B, Analytical technologies in the biomedical and life sciences 2018;1085:21-9 doi 10.1016/j.jchromb.2018.03.043.
Dong Z, Yu D, Liu Q, Ding Z, Lyons VJ, Bright RK, et al. Enhanced capture and release of circulating tumor cells using hollow glass microspheres with a nanostructured surface. Nanoscale 2018;10(35):16795-804 doi 10.1039/c8nr04434a.
Garcia K, Pham H, Sharma P. Narcotic Pain Control for Ureterolithiasis Is Associated With Unnecessary Repeat Imaging in the Emergency Department. Journal for healthcare quality : official publication of the National Association for Healthcare Quality 2018 doi 10.1097/jhq.0000000000000165.
Grozdanov PN, Masoumzadeh E, Latham MP, MacDonald CC. The structural basis of CstF-77 modulation of cleavage and polyadenylation through stimulation of CstF-64 activity. Nucleic Acids Research 2018 doi 10.1093/nar/gky862.
Jarvis C, Nelius T, Martinez-Marin D, Sennoune SR, Filleur S. Cabazitaxel regimens inhibit the growth of prostate cancer cells and enhances the anti-tumor properties of PEDF with various efficacy and toxicity. The Prostate 2018;78(12):905-14 doi 10.1002/pros.23647.
Karamysheva ZN, Tikhonova EB, Grozdanov PN, Huffman JC, Baca KR, Karamyshev A, et al. Polysome Profiling in Leishmania, Human Cells and Mouse Testis. Journal of visualized experiments : JoVE 2018(134) doi 10.3791/57600.
Keyel ME, Reynolds CP. Spotlight on dinutuximab in the treatment of high-risk neuroblastoma: development and place in therapy. Biologics : targets & therapy. 2018;13:1-12.
Khalil S, Al-Rahawan MG, Al-Rahawan MM. Periosteal mesenchymal chondrosarcoma of the tibia. Skeletal Radiology 2018;47(5):605 doi 10.1007/s00256-018-2885-9.
Kirkpatick C HA, Shiarma P. Antibiotic prophylaxis is not associated with reduced urinary tract infection-related complications after cystectomy and ileal conduit. Bladder 2018;5:e35.
Kou L, Bhutia YD, Yao Q, He Z, Sun J, Ganapathy V. Transporter-Guided Delivery of Nanoparticles to Improve Drug Permeation across Cellular Barriers and Drug Exposure to Selective Cell Types. Frontiers in pharmacology 2018;9:27 doi 10.3389/fphar.2018.00027.
Kou L, Sun R, Ganapathy V, Yao Q, Chen R. Recent advances in drug delivery via the organic cation/carnitine transporter 2 (OCTN2/SLC22A5). Expert Opinion on Therapeutic targets 2018;22(8):715-26 doi 10.1080/14728222.2018.1502273.
Kurmasheva RT, Kurmashev D, Reynolds CP, Kang M, Wu J, Houghton PJ, et al. Initial testing (stage 1) of M6620 (formerly VX-970), a novel ATR inhibitor, alone and combined with cisplatin and melphalan, by the Pediatric Preclinical Testing Program. Pediatric Blood & Cancer 2018;65(2) doi 10.1002/pbc.26825.
Lairson DR, Kim J, Byrd T, Salaiz R, Shokar NK. Cost-Effectiveness of Community Interventions for Colorectal Cancer Screening: Low-Income Hispanic Population. Health Promotion Practice 2018;19(6):863-72 doi 10.1177/1524839917750815.
Lunney A, Haynes A, Sharma P. Moderate or severe LUTS is associated with increased recurrence of non - muscle - invasive urothelial carcinoma of the bladder. International Braz J Urol : 2018;44 doi 10.1590/s1677-5538.Ibju.2018.0068.
Makena MR, Cho HE, Nguyen TH, Koneru B, Verlekar DU, Hindle A, Min H. Kang MH, Reynolds CP: Cytotoxic activity of difluoromethylornithine compared with fenretinide in neuroblastoma cell lines. Pediatric Blood & Cancer 24:e27447, 2018. PMID: 30251395
Martinez-Marin DJC, Nelius T, Filleur S. Assessment of phagocytic activity in live macrophase-prostate tumor cell co-cultures by confocal, Nomarski, and spectral imaging. Biology Methods & Protocols 2018;In Press.
Mycielska ME, Dettmer K, Rummele P, Schmidt K, Prehn C, Milenkovic VM, et al. Extracellular Citrate Affects Critical Elements of Cancer Cell Metabolism and Supports Cancer Development In Vivo. Cancer research 2018;78(10):2513-23 doi 10.1158/0008-5472.Can-17-2959.
Nguyen TH, Pham T, Strickland T, Brewer D, Belirgen M, Al-Rahawan MM. Von Hippel-Lindau with early onset of hemangioblastoma and multiple drop-metastases like spinal lesions: A case report. Medicine 2018;97(39):e12477 doi 10.1097/md.0000000000012477.
Ogura J, Babu E, Miyauchi S, Ramachandran S, Nemeth E, Bhutia YD, et al. Retraction Note: Identification of a novel Na(+)-coupled Fe(3+)-citrate transport system, distinct from mammalian INDY, for uptake of citrate in mammalian cells. Scientific Reports 2018;8(1):11021 doi 10.1038/s41598-018-28645-x.
Ogura J, Babu E, Miyauchi S, Ramachandran S, Nemeth E, Bhutia YD, et al. Identification of a novel Na(+)-coupled Fe(3+)-citrate transport system, distinct from mammalian INDY, for uptake of citrate in mammalian cells. Scientific Reports 2018;8(1):2519 doi 10.1038/s41598-018-20620-w.
Ozkaynak MF, Gilman AL, London WB, Naranjo A, Diccianni MB, Tenney SC, et al. Corrigendum: A Comprehensive Safety Trial of Chimeric Antibody 14.18 With GM-CSF, IL-2, and Isotretinoin in High-Risk Neuroblastoma Patients Following Myeloablative Therapy: Children's Oncology Group Study ANBL0931. Frontiers in Immunology 2018;9:1641 doi 10.3389/fimmu.2018.01641.
P S. Three-diminsional printing in urology: History, current applications, and future directions. Urology 2018;In Press.
Parikh N, Sharma P. Three-Dimensional Printing in Urology: History, Current Applications, and Future Directions. Urology 2018 doi 10.1016/j.urology.2018.08.004.
Pham H, Sharma P. Emerging, newly-approved treatments for lower urinary tract symptoms secondary to benign prostatic hypertrophy. The Canadian journal of urology 2018;25(2):9228-37.
Pinto N, DuBois SG, Marachelian A, Diede SJ, Taraseviciute A, Glade Bender JL, et al. Phase I study of vorinostat in combination with isotretinoin in patients with refractory/recurrent neuroblastoma: A new approaches to Neuroblastoma Therapy (NANT) trial. Pediatric Blood & Cancer 2018;65(7):e27023 doi 10.1002/pbc.27023.
Ranganathan P, Shanmugam A, Swafford D, Suryawanshi A, Bhattacharjee P, Hussein MS, et al. GPR81, a Cell-Surface Receptor for Lactate, Regulates Intestinal Homeostasis and Protects Mice from Experimental Colitis. Journal of Immunology (Baltimore, Md : 1950) 2018;200(5):1781-9 doi 10.4049/jimmunol.1700604.
Sharma M, Castro-Piedras I, Simmons GE, Jr., Pruitt K. Dishevelled: A masterful conductor of complex Wnt signals. Cellular Signalling 2018;47:52-64 doi 10.1016/j.cellsig.2018.03.004.
Torres H, Sharma P. Bilateral emphysematous pyelonephritis. Urology Case Reports 2018;17:119-21 doi 10.1016/j.eucr.2018.01.028.
Verlekar D, Wei SJ, Cho H, Yang S, Kang MH. Ceramide synthase-6 confers resistance to chemotherapy by binding to CD95/Fas in T-cell acute lymphoblastic leukemia. Cell Death & Disease 2018;9(9):925 doi 10.1038/s41419-018-0964-4.
Yu H AJ, Chen Y, Groblewski G, Cantrill L, Frost S, Bright RK, Khushi M, Byrne JA. Delayed recruting of TPD52 to lipid droplets - eveidence for a "second wave" of lipid droplet-associated proteins that respond to altered lipid storage induced by Brefeldin A treatment. BBA Molecular and Cell Biology of Lipids 2018;In Press.
Zargar-Shoshtari K, Sharma P, Spiess PE. Insight into novel biomarkers in penile cancer: Redefining the present and future treatment paradigm? Urologic Oncology 2018;36(10):433-9 doi 10.1016/j.urolonc.2017.10.010.
Zoghbi ME, Altenberg GA. Luminescence resonance energy transfer spectroscopy of ATP-binding cassette proteins. Biochimica et Biophysica Acta Biomembranes 2018;1860(4):854-67 doi 10.1016/j.bbamem.2017.08.005.
Zuckerman MJ, Schmulson MJ, Bashashati M, Jia Y, Dwivedi A, Ortiz M, et al. Irritable Bowel Syndrome on the US Mexico Border: A Survey in an Indigent Population Using Rome III Criteria. Journal of Clinical Gastroenterology 2018;52(7):622-7 doi 10.1097/mcg.0000000000000898.

Cho, H.E., Min, H.K. (2017). Analysis of fenretinide and its metabolitesin human plasma by liquid chromatography-tandem mass spectrometryand its application to clinical pharmacokinetics. J Pharm Biomed Anal 132,117-24. PM:27701038
Cooper, J.P., Reynolds, C.P., Cho, H., Kang, M.H. (2017). Clinical development of fenretinide as an antineoplastic drug: Pharmacology perspectives. Exp Biol Med (Maywood) 242, 1178-84. PM:28429653
Coothankandaswamy, V., Cao, S., Xu, Y., Prasad, P.D., Singh, P.K.,Reynolds, C.P.,
Yang, S., Ogura, J., Ganapathy, V., Bhutia, Y.D. (2016). Amino acid transporter SLC6A14 is a novel and effective drug target for pancreatic cancer. Br J Pharmacol, PM:27747870
Fendley GA, Urbatsch IL, Sutton RB, Zoghbi ME, Altenberg G.A. (2017). Nucleotide dependence of the dimerization of ATP binding cassette nucleotide binding domains. Biochem. Biophys. Res Commun. In Press.
Harenza, J.L., Diamond, M.A., Adams, R.N., Song, M.M., Davidson, H.L.,Hart, L.S., Dent, M.H., Fortina, P., Reynolds, C.P., Maris, J.M. (2017). Transcriptomic profiling of 39 commonly-used neuroblastoma cell lines. SciData 4, 170033. PM:28350380
Kurmasheva, R.T., Gorlick, R., Kolb, E.A., Keir, S.T., Maris, J.M., Lock,R.B., Carol, H., Kang, M., Reynolds, C.P., Wu, J., Houghton, P.J., Smith,M.A. (2017). Initial testing of VS-4718, a novel inhibitor of focal adhesion kinase (FAK), against pediatric tumor models by the Pediatric Preclinical Testing Program. Pediatr Blood Cancer 64, PM:27786412
Kurmasheva RT, Kurmashev D, Reynolds CP, Kang M, Wu J, Houghton PJ, Smith MA. Initial testing (stage 1) of M6620 (formerly VX-970), a novel ATR inhibitor, alone and combined with cisplatin and melphalan, by the Pediatric Preclinical Testing Program. Pediatr Blood Cancer. 2017 PMID: 28921800
Li, W., Zhang, Y., Reynolds, C.P., Pappas, D. ( 2017) . Microfluidic Separation of Lymphoblasts for the Isolation of Acute Lymphoblastic Leukemia Using the Human Transferrin Receptor as a Capture Target. Anal Chem 89, 7340-7. PM:28656755
Lock, R., Carol, H., Maris, J.M., Kolb, E.A., Gorlick, R., Reynolds, C.P.,Kang, M.H., Keir, S.T., Wu, J., Purmal, A., Gudkov, A., Kurmashev, D.,Kurmasheva, R.T., Houghton, P.J., Smith, M.A. (2017). Initial testing (stage 1) of the curaxin CBL0137 by the pediatric preclinical testing program. Pediatr Blood Cancer 64, PM:27650817
Lopez-Barcons, L., Maurer, B.J., Kang, M.H., Reynolds, C.P. (2017). P450 inhibitor ketoconazole increased the intratumor drug levels and antitumor activity of fenretinide in human neuroblastoma xenograft models. Int J Cancer 141, 405-13. PM:28340497
Makena, M.R., Koneru, B., Nguyen, T.H., Kang, M.H., Reynolds, C.P. (2017). Reactive Oxygen Species-Mediated Synergism of Fenretinide and Romidepsin in Preclinical Models of T-cell Lymphoid Malignancies. Mol Cancer Ther 16, 649-61. PM:28119491
Mohrbacher A, Yang AS, Groshen S, Kummar S, Gutierrez ME, Kang MH, Tsao-Wei D, Reynolds CP, Newman E, Maurer BJ: Phase I study of fenretinide delivered intravenously in patients with relapsed or refractory hematologic malignancies: a California Cancer Consortium Trial. Clinical Cancer Res 23:4550-4555, 2017. PMID: 28420721
Penaranda E, Moloku J, Hernandez I, Salaiz R, Nguyen N, Byrd T.L.,Fernandez M.E. (2017). Attitudes towards self-sampling for HPV infection for cervical cancer screening among primary care attendees on the US-Mexico border. Southern Medical Journal In Press.

Arjunan, P., Gnanaprakasam, J.P., Ananth, S., Romej, M.A., Rajalakshmi,V.K., Prasad, P.D., Martin, P.M., Gurusamy, M., Thangaraju, M., Bhutia,Y.D., Ganapathy, V. (2016) . Increased Retinal Expression of the Pro-Angiogenic Receptor GPR91 via BMP6 in a Mouse Model of Juvenile Hemochromatosis. Invest Ophthalmol Vis Sci 57, 1612-9.
Attiyeh, E.F., Maris, J.M., Lock, R., Reynolds, C.P., Kang, M.H., Carol, H.,Gorlick, R., Kolb, E.A., Keir, S.T., Wu, J., Landesman, Y., Shacham, S.,Lyalin, D., Kurmasheva, R.T., Houghton, P.J., Smith, M.A. (2016). Pharmacodynamic and genomic markers associated with response to the XPO1/CRM1 inhibitor selinexor (KPT-330) : A report from the pediatric preclinical testing program. Pediatr Blood Cancer 63, 276-86. PM:26398108
Bhutia, Y.D., Babu, E., Ganapathy, V. (2016). Re-programming tumour cell metabolism to treat cancer: no lone target for lonidamine. Biochem J 473, 1503-6.
Bhutia, Y.D., Babu, E., Ramachandran, S., Yang, S., Thangaraju, M., Ganapathy, V. (2016). SLC transporters as a novel class of tumour suppressors: identity, function and molecular mechanisms. Biochem J 473,1113-24.
Bhutia, Y.D., Ganapathy, V. (2016) . Glutamine transporters inmammalian cells and their functions in physiology and cancer. Biochim Biophys Acta 1863, 2531-9.
Dalamon, V., Fiori, M.C., Figueroa, V.A., Oliva, C.A., Del, R.R., Gonzalez,W., Canan, J., Elgoyhen, A.B., Altenberg, G.A., Retamal, M.A. (2016). Gap-junctional channel and hemichannel activity of two recently identified connexin 26 mutants associated with deafness. Pflugers Arch 468, 909-18.
Dykes, S.S., Gray, A.L., Coleman, D.T., Saxena, M., Stephens, C.A.,Carroll, J.L., Pruitt, K., Cardelli, J.A. (2016). The Arf-like GTPase Arl8bis essential for three-dimensional invasive growth of prostate cancer in vitroand xenograft formation and growth in vivo. Oncotarget 7, 31037-52.
Gorlick, R., Kolb, E.A., Keir, S.T., Maris, J.M., Lock, R.B., Carol, H., Reynolds, C.P., Kang, M.H., Billups, C.A., Collins, J., Kurmashev, D., Kurmasheva, R.T., Houghton, P.J., Smith, M.A. (2016). Initial Testing of NSC 750854, a Novel Purine Analog, Against Pediatric Tumor Models bythe Pediatric Preclinical Testing Program. Pediatr Blood Cancer 63,443-50. PM:26797892
Grozdanov, P.N., Amatullah, A., Graber, J.H., MacDonald, C.C. (2016) .TauCstF-64 Mediates Correct mRNA Polyadenylation and Splicing of Activator and Repressor Isoforms of the Cyclic AMP-Responsive ElementModulator (CREM) in Mouse Testis. Biol Reprod 94, 34.
Hall, C.P., Reynolds, C.P., Kang, M.H. (2016). Modulation ofGlucocorticoid Resistance in Pediatric T-cell Acute Lymphoblastic Leukemia by Increasing BIM Expression with the PI3K/mTOR Inhibitor BEZ235. Clin Cancer Res 22, 621-32. PM:26080839
Harris, J.C., Martinez, J.M., Grozdanov, P.N., Bergeson, S.E., Grammas, P., MacDonald, C.C. (2016) . The Cstf2t Polyadenylation Gene Plays a Sex-Specific Role in Learning Behaviors in Mice. PLoS One 11, e0165976.
Irving, B.A., Wood, G.C., Bennotti, P.N., Babu, E., Deshpande, A., Lent,M.R., Petrick, A., Gabrielsen, J., Strodel, W., Gerhard, G.S., Still, C.D., Ganapathy, V., Rolston, D.D. (2016) . Nutrient Transporter Expression in the Jejunum in Relation to Body Mass Index in Patients Undergoing Bariatric Surgery. Nutrients 8, E683.
Kang, M.H., Reynolds, C.P., Kolb, E.A., Gorlick, R., Carol, H., Lock, R.,Keir, S.T., Maris, J.M., Wu, J., Lyalin, D., Kurmasheva, R.T., Houghton,P.J., Smith, M.A. (2016) . Initial Testing (Stage 1) of MK-8242-A Novel MDM2 Inhibitor-by the Pediatric Preclinical Testing Program. Pediatr Blood Cancer 63, 1744-52. PM:27238606
Krishnan, S., Fiori, M.C., Whisenant, T.E., Cortes, D.M., Altenberg, G.A., Cuello, L.G. (2016). An Escherichia coli-Based Assay to Assess the Function of Recombinant Human Hemichannels. J Biomol Screen,1087057116675321.
Krytska, K., Ryles, H.T., Sano, R., Raman, P., Infarinato, N.R., Hansel,T.D., Makena, M.R., Song, M.M., Reynolds, C.P., Mosse, Y.P. (2016). Crizotinib Synergizes with Chemotherapy in Preclinical Models of Neuroblastoma. Clin Cancer Res 22, 948-60. PM:26438783
Le, Y.L., McFall, S.L., Byrd, T.L., Volk, R.J., Cantor, S.B., Kuban, D.A., Mullen, P.D. (2016). Is "Active Surveillance" an Acceptable Alternative?: A Qualitative Study of Couples' Decision Making about Early-Stage,Localized Prostate Cancer. Narrat Inq Bioeth 6, 51-61.
Lock, R., Carol, H., Maris, J.M., Kolb, E.A., Gorlick, R., Reynolds, C.P.,Kang, M.H., Keir, S.T., Wu, J., Purmal, A., Gudkov, A., Kurmashev, D.,Kurmasheva, R.T., Houghton, P.J., Smith, M.A. (2016). Initial testing (stage 1) of the curaxin CBL0137 by the pediatric preclinical testing program. Pediatr Blood Cancer, PM:27650817
Luo, Q., Gong, P., Sun, M., Kou, L., Ganapathy, V., Jing, Y., He, Z., Sun,J. (2016). Transporter occluded-state conformation-inducedendocytosis: Amino acid transporter ATB0,+-mediated tumor targeting of liposomes for docetaxel delivery for hepatocarcinoma therapy. J Control Release 243:370-380. doi: 10.1016/j.jconrel.2016.10.031. Epub; 2016 Nov 1., 370-80.
Manna, P.R., Stetson, C.L., Slominski, A.T., Pruitt, K. (2016). Role of the steroidogenic acute regulatory protein in health and disease. Endocrine 51, 7-21.
Murphy, B., Yin, H., Maris, J.M., Kolb, E.A., Gorlick, R., Reynolds, C.P.,Kang, M.H., Keir, S.T., Kurmasheva, R.T., Dvorchik, I., Wu, J., Billups,C.A., Boateng, N., Smith, M.A., Lock, R.B., Houghton, P.J. (2016). Evaluation of Alternative In Vivo Drug Screening Methodology: A Single Mouse Analysis. Cancer Res 76, 5798-809. PM:27496711
Pathania, R., Ramachandran, S., Mariappan, G., Thakur, P., Shi, H., Choi,J.H., Manicassamy, S., Kolhe, R., Prasad, P.D., Sharma, S., Lokeshwar, B.L., Ganapathy, V., Thangaraju, M. (2016). Combined Inhibition of DNMT and HDAC Blocks the Tumorigenicity of Cancer Stem-like Cells and Attenuates Mammary Tumor Growth. Cancer Res 76, 3224-35.
Promsote, W., Powell, F.L., Veean, S., Thounaojam, M., Markand, S.,Saul, A., Gutsaeva, D., Bartoli, M., Smith, S.B., Ganapathy, V., Martin,P.M. (2016). Oral Monomethyl Fumarate Therapy Ameliorates Retinopathy in a Humanized Mouse Model of Sickle Cell Disease. Antioxid Redox Signal 25, 921-35.
Pruitt, K. (2016). Molecular and Cellular Changes During CancerProgression Resulting From Genetic and Epigenetic Alterations. Prog Mol Biol Transl Sci 144:3-47. doi: 10.1016/bs.pmbts.2016.09.001. Epub; 2016 Oct 7., 3-47.
Shanmugam, A.K., Mysona, B.A., Wang, J., Zhao, J., Tawfik, A., Sanders,A., Markand, S., Zorrilla, E., Ganapathy, V., Bollinger, K.E., Smith, S.B.(2016). Progesterone Receptor Membrane Component 1 (PGRMC1) Expression in Murine Retina. Curr Eye Res 41, 1105-12.
Sivaprakasam, S., Gurav, A., Paschall, A.V., Coe, G.L., Chaudhary, K.,Cai, Y., Kolhe, R., Martin, P., Browning, D., Huang, L., Shi, H., Sifuentes,H., Vijay-Kumar, M., Thompson, S.A., Munn, D.H., Mellor, A., McGaha,T.L., Shiao, P., Cutler, C.W., Liu, K., Ganapathy, V., Li, H., Singh, N. (2016). An essential role of Ffar2 (Gpr43) in dietary fibre-mediated promotion of healthy composition of gut microbiota and suppression ofintestinal carcinogenesis. Oncogenesis 5, e238.
Thompson, B., Carosso, E.A., Jhingan, E., Wang, L., Holte, S.E., Byrd,T.L., Benavides, M.C., Lopez, C., Martinez-Gutierrez, J., Ibarra, G., Gonzalez, V.J., Gonzalez, N.E., Duggan, C.R. (2016). Results of arandomized controlled trial to increase cervical cancer screening among rural Latinas. Cancer, 10.
Thu, K.L., Papari-Zareei, M., Stastny, V., Song, K., Peyton, M., Martinez,V.D., Zhang, Y.A., Castro, I.B., Varella-Garcia, M., Liang, H., Xing, C.,Kittler, R., Milchgrub, S., Castrillon, D.H., Davidson, H.L., Reynolds, C.P.,Lam, W.L., Lea, J., Gazdar, A.F. (2016) . A comprehensively characterized cell line panel highly representative of clinical ovarian high-grade serous carcinomas. Oncotarget, PM:27302921
Villablanca, J.G., Volchenboum, S.L., Cho, H., Kang, M.H., Cohn, S.L., Anderson, C.P., Marachelian, A., Groshen, S., Tsao-Wei, D., Matthay, K.K., Maris, J.M., Hasenauer, C.E., Czarnecki, S., Lai, H., Goodarzian, F.,Shimada, H., Reynolds, C.P. (2016) . A Phase I New Approaches to Neuroblastoma Therapy Study of Buthionine Sulfoximine and Melphalan With Autologous Stem Cells for Recurrent/Refractory High-Risk Neuroblastoma. Pediatr Blood Cancer 63, 1349-56. PM:27092812
Zoghbi, M.E., Cooper, R.S., Altenberg, G.A. (2016) . The Lipid Bilayer Modulates the Structure and Function of an ATP-binding Cassette Exporter. J Biol Chem 291, 4453-61.

Anderson, C.P., Matthay, K.K., Perentesis, J.P., Neglia, J.P., Bailey, H.H.,Villablanca, J.G., Groshen, S., Hasenauer, B., Maris, J.M., Seeger, R.C.,Reynolds, C.P. (2015). Pilot study of intravenous melphalan combined with continuous infusion L-S,R-buthionine sulfoximine for children with recurrent neuroblastoma. Pediatr Blood Cancer 62, 1739-46. PM:26153194
Babu, E., Bhutia, Y.D., Ramachandran, S., Gnanaprakasam, J.P., Prasad,P.D., Thangaraju, M., Ganapathy, V. (2015). Deletion of the amino acid transporter Slc6a14 suppresses tumour growth in spontaneous mouse models of breast cancer. Biochem J 469, 17-23.
Bhutia, Y.D., Ganapathy, V. (2015). Short, but Smart: SCFAs Train TCells in the Gut to Fight Autoimmunity in the Brain. Immunity 20;43,629-31.
Bhutia, Y.D., Babu, E., Ramachandran, S., Ganapathy, V. (2015). Amino Acid transporters in cancer and their relevance to "glutamine addiction": novel targets for the design of a new class of anticancer drugs. Cancer Res 75, 1782-8.
Bhutia, Y.D., Babu, E., Ganapathy, V. (2015). Interferon-gamma induces a tryptophan-selective amino acid transporter in human colonicepithelial cells and mouse dendritic cells. Biochim Biophys Acta 1848,453-62.
Fernandez, M.E., Savas, L.S., Wilson, K.M., Byrd, T.L., Atkinson, J.,Torres-Vigil, I., Vernon, S.W. (2015). Colorectal cancer screening among Latinos in three communities on the Texas-Mexico border. Health Educ Behav 42, 16-25.
Fiori, M.C., Krishnan, S., Cortes, D.M., Retamal, M.A., Reuss, L.,Altenberg, G.A., Cuello, L.G. (2015). Functional hemichannels formed by human connexin 26 expressed in bacteria. Biosci Rep 35, e00177.
Gopal, E., Babu, E., Ramachandran, S., Bhutia, Y.D., Prasad, P.D.,Ganapathy, V. (2015). Species-specific influence of lithium on the activity of SLC13A5 (NaCT) : lithium-induced activation is specific for the transporter in primates. J Pharmacol Exp Ther 353, 17-26.
Grozdanov, P.N., MacDonald, C.C. (2015). Generation of plasmid vectors expressing FLAG-tagged proteins under the regulation of humanelongation factor-1alpha promoter using Gibson assembly. J Vis Exp, 10.
Gurav, A., Sivaprakasam, S., Bhutia, Y.D., Boettger, T., Singh, N.,Ganapathy, V. (2015). Slc5a8, a Na+-coupled high-affinity transporter for short-chain fatty acids, is a conditional tumour suppressor in colon thatprotects against colitis and colon cancer under low-fibre dietary conditions. Biochem J 469, 267-78.
Kamili, A., Roslan, N., Frost, S., Cantrill, L.C., Wang, D., Della-Franca, A., Bright, R.K., Groblewski, G.E., Straub, B.K., Hoy, A.J., Chen, Y., Byrne,J.A. (2015). TPD52 expression increases neutral lipid storage within cultured cells. J Cell Sci 128, 3223-38.
Kang, M.H., Wang, J., Makena, M.R., Lee, J.S., Paz, N., Hall, C.P., Song, M.M., Calderon, R.I., Cruz, R.E., Hindle, A., Ko, W., Fitzgerald, J.B.,Drummond, D.C., Triche, T.J., Reynolds, C.P. (2015) . Activity of MM-398, nanoliposomal irinotecan (nal-IRI), in Ewing's family tumorxenografts is associated with high exposure of tumor to drug and high SLFN11 expression. Clin Cancer Res 21, 1139-50. PM:25733708
Kolb, E.A., Gorlick, R., Keir, S.T., Maris, J.M., Kang, M.H., Reynolds, C.P.,Lock, R.B., Carol, H., Wu, J., Kurmasheva, R.T., Houghton, P.J., Smith, M.A. (2015). Initial testing (stage 1) of BAL101553, a novel tubulin binding agent, by the pediatric preclinical testing program. Pediatr Blood Cancer 62, 1106-9. PM:25407467
Manna, P.R., Stetson, C.L., Daugherty, C., Shimizu, I., Syapin, P.J., Garrel, G., Cohen-Tannoudji, J., Huhtaniemi, I., Slominski, A.T., Pruitt, K., Stocco, D.M. (2015). Up-regulation of steroid biosynthesis by retinoid signaling: Implications for aging. Mech Ageing Dev 150:74-82. doi: 10.1016j.mad.2015.08.007. Epub; 2015 Aug 21., 74-82.
Manna, P.R., Sennoune, S.R., Martinez-Zaguilan, R., Slominski, A.T.,Pruitt, K. (2015). Regulation of retinoid mediated cholesterol efflux involves liver X receptor activation in mouse macrophages. Biochem Biophys Res Commun 464, 312-7.
McFall, S.L., Mullen, P.D., Byrd, T.L., Cantor, S.B., Le, Y.C., Torres-Vigil, I., Pettaway, C., Volk, R.J. (2015). Treatment decisions for localized prostate cancer: a concept mapping approach. Health Expect 18, 2079-90.
Pandey, S., Simmons, G.E., Jr., Malyarchuk, S., Calhoun, T.N., Pruitt, K. (2015). A novel MeCP2 acetylation site regulates interaction with ATRX and HDAC1. Genes Cancer 6, 408-21.
Reynolds, C.P., Kang, M.H., Maris, J.M., Kolb, E.A., Gorlick, R., Wu, J.,Kurmasheva, R.T., Houghton, P.J., Smith, M.A. (2015). Initial testing (stage 1) of the anti-microtubule agents cabazitaxel and docetaxel, by the pediatric preclinical testing program. Pediatr Blood Cancer 62,1897-905. PM:26154614
Roncancio, A.M., Ward, K.K., Sanchez, I.A., Cano, M.A., Byrd, T.L.,Vernon, S.W., Fernandez-Esquer, M.E., Fernandez, M.E. (2015). Using the Theory of Planned Behavior to Understand Cervical Cancer Screening Among Latinas. Health Educ Behav 42, 621-6.
.Seidel, D., Shibina, A., Siebert, N., Wels, W.S., Reynolds, C.P., Huebener,N., Lode, H.N. (2015). Disialoganglioside-specific human natural killer cells are effective against drug-resistant neuroblastoma. Cancer Immunol Immunother 64, 621-34. PM:25711293
Sheard, M.A., Ghent, M.V., Cabral, D.J., Lee, J.C., Khankaldyyan, V., Ji,L., Wu, S.Q., Kang, M.H., Sposto, R., Asgharzadeh, S., Reynolds, C.P. (2015). Preservation of high glycolytic phenotype by establishing new acute lymphoblastic leukemia cell lines at physiologic oxygen concentration. Exp Cell Res 334, 78-89. PM:25845499
Simmons, G.E., Jr., Pruitt, W.M., Pruitt, K. (2015). Diverse roles of SIRT1 in cancer biology and lipid metabolism. Int J Mol Sci 16, 950-65.
Smith, M.A., Reynolds, C.P., Kang, M.H., Kolb, E.A., Gorlick, R., Carol, H.,Lock, R.B., Keir, S.T., Maris, J.M., Billups, C.A., Lyalin, D., Kurmasheva,R.T., Houghton, P.J. (2015). Synergistic activity of PARP inhibition by talazoparib (BMN 673) with temozolomide in pediatric cancer models in the pediatric preclinical testing program. Clin Cancer Res 21, 819-32.PM:25500058
Smith, M.A., Hampton, O.A., Reynolds, C.P., Kang, M.H., Maris, J.M.,Gorlick, R., Kolb, E.A., Lock, R., Carol, H., Keir, S.T., Wu, J., Kurmasheva, R.T., Wheeler, D.A., Houghton, P.J. (2015). Initial testing (stage 1) ofthe PARP inhibitor BMN 673 by the pediatric preclinical testing program: PALB2 mutation predicts exceptional in vivo response to BMN 673. Pediatr Blood Cancer 62, 91-8. PM:25263539

Alfano, R., Youngblood, B.A., Zhang, D., Huang, N., MacDonald, C.C.(2014). Human leukemia inhibitory factor produced by the ExpressTec method from rice (Oryza sativa L.) is active in human neural stem cells and mouse induced pluripotent stem cells. Bioengineered 5, 180-5.
Bright, R.K., Bright, J.D., Byrne, J.A. (2014). Overexpressed oncogenictumor-self antigens. Hum Vaccin Immunother10, 3297-305.
Byrne, J.A., Frost, S., Chen, Y., Bright, R.K. (2014). Tumor protein D52(TPD52) and cancer-oncogene understudy or understudied oncogene? Tumour Biol 35, 7369-82.
Carol, H., Maris, J.M., Kang, M.H., Reynolds, C.P., Kolb, E.A., Gorlick, R., Keir, S.T., Wu, J., Kurmasheva, R.T., Houghton, P.J., Smith, M.A., Lock, R.B., Lyalin, D. (2014). Initial testing (stage 1) of the notch inhibitor PF-03084014, by the pediatric preclinical testing program. Pediatr Blood Cancer 61, 1493-6. PM:24664981
Carol, H., Gorlick, R., Kolb, E.A., Morton, C.L., Manesh, D.M., Keir, S.T., Reynolds, C.P., Kang, M.H., Maris, J.M., Wozniak, A., Hickson, I., Lyalin, D., Kurmasheva, R.T., Houghton, P.J., Smith, M.A., Lock, R. (2014). Initial testing (stage 1) of the histone deacetylase inhibitor, quisinostat (JNJ-26481585), by the Pediatric Preclinical Testing Program. Pediatr Blood Cancer 61, 245-52. PM:24038993
Farooqi, A.S., Dagg, R.A., Choi, L.M., Shay, J.W., Reynolds, C.P., Lau,L.M. (2014). Alternative lengthening of telomeres in neuroblastoma cell lines is associated with a lack of MYCN genomic amplification and with p53 pathway aberrations. J Neurooncol 119, 17-26. PM:24792489
Fiori, M.C., Reuss, L., Cuello, L.G., Altenberg, G.A. (2014). Functional analysis and regulation of purified connexin hemichannels. Front Physiol 5:71. doi: 10.3389/fphys.2014.00071. eCollection; 2014.,71.
Gorlick, R., Kolb, E.A., Keir, S.T., Maris, J.M., Reynolds, C.P., Kang, M.H.,Carol, H., Lock, R., Billups, C.A., Kurmasheva, R.T., Houghton, P.J., Smith, M.A. (2014). Initial testing (stage 1) of the Polo-like kinase inhibitor volasertib (BI 6727), by the Pediatric Preclinical Testing Program. Pediatr Blood Cancer 61, 158-64. PM:23956067
Grozdanov, P.N., MacDonald, C.C. (2014). High-throughput sequencing of RNA isolated by cross-linking and immunoprecipitation (HITS-CLIP) to determine sites of binding of CstF-64 on nascent RNAs. Methods Mol Biol 1125:187-208. doi: 10.1007/978-1-62703-971-0_ 17., 187-208.
Hockert, J.A., MacDonald, C.C. (2014). The stem-loop luciferase assay for polyadenylation (SLAP) method for determining CstF-64-dependentpolyadenylation activity. Methods Mol Biol 1125:109-17. doi: 10.1007978-1-62703-971-0_ 9., 109-17.
Houghton, P.J., Kurmasheva, R.T., Lyalin, D., Maris, J.M., Kolb, E.A.,Gorlick, R., Reynolds, C.P., Kang, M.H., Keir, S.T., Wu, J., Smith, M.A. (2014). Initial solid tumor testing (stage 1) of AZD1480, an inhibitor of Janus kinases 1 and 2 by the pediatric preclinical testing program. Pediatr Blood Cancer 61, 1972-9. PM:25131802
Kang, M.H., Villablanca, J.G., Glade Bender, J.L., Matthay, K.K., Groshen,S., Sposto, R., Czarnecki, S., Ames, M.M., Reynolds, C.P., Marachelian,A., Maurer, B.J. (2014). Probable fatal drug interaction between intravenous fenretinide, ceftriaxone, and acetaminophen: a case report from a New Approaches to Neuroblastoma (NANT) Phase I study. BMC Res Notes 7, 256. PM:247554753
Kang, M.H., Reynolds, C.P., Maris, J.M., Gorlick, R., Kolb, E.A., Lock, R.,Carol, H., Keir, S.T., Wu, J., Lyalin, D., Kurmasheva, R.T., Houghton, P.J.,Smith, M.A. (2014). Initial testing (stage 1) of the investigational mTOR kinase inhibitor MLN0128 by the pediatric preclinical testing program. Pediatr Blood Cancer 61, 1486-9. PM:24623675
Kurmasheva, R.T., Reynolds, C.P., Kang, M.H., Allievi, C., Houghton, P.J.,Smith, M.A. (2014). Initial testing (stage 1) of the topoisomerase II inhibitor pixantrone, by the pediatric preclinical testing program. Pediatr Blood Cancer 61, 922-4. PM:24166988
Lairson, D.R., Chang, Y.C., Byrd, T.L., Lee, S.J., Fernandez, M.E., Wilson,K.M. (2014). Cervical cancer screening with AMIGAS: a cost-effectiveness analysis. Am J Prev Med 46, 617-23.
Leon-Paravic, C.G., Figueroa, V.A., Guzman, D.J., Valderrama, C.F., Vallejos, A.A., Fiori, M.C., Altenberg, G.A., Reuss, L., Retamal, M.A.(2014). Carbon monoxide (CO) is a novel inhibitor of connexin hemichannels. J Biol Chem 289, 36150-7.
Nelius, T., Martinez-Marin, D., Hirsch, J., Miller, B., Rinard, K., Lopez, J.,de, R.W., Filleur, S. (2014). Pigment epithelium-derived factorexpression prolongs survival and enhances the cytotoxicity of low-dose chemotherapy in castration-refractory prostate cancer. Cell Death Dis 5,e1210. PM:24810046
Roslan, N., Bieche, I., Bright, R.K., Lidereau, R., Chen, Y., Byrne, J.A. (2014). TPD52 represents a survival factor in ERBB2-amplified breast cancer cells. Mol Carcinog 53, 807-19.
Ryu, Y., Hall, C.P., Reynolds, C.P., Kang, M.H. (2014). Caspase-dependent Mcl-1 cleavage and effect of Mcl-1 phosphorylation in ABT-737-induced apoptosis in human acute lymphoblastic leukemia celllines. Exp Biol Med (Maywood) 239, 1390-402. PM:24951472
Sennoune, S.R., Bermudez, L.E., Lees, J.C., Hirsch, J., Filleur, S.,Martinez-Zaguilan, R. (2014). Vacuolar H+-ATPase is down-regulatedby the angiogenesis-inhibitory pigment epithelium-derived factor inmetastatic prostate cancer cells. Cell Mol Biol (Noisy-le-grand) 60,45-52. PM:24857383
Shah, E.D., Fisch, B.M., Arceci, R.J., Buckley, J.D., Reaman, G.H.,Sorensen, P.H., Triche, T.J., Reynolds, C.P. (2014). DrugPath: a database for academic investigators to match oncology molecular targets with drugs in development. Cancer Chemother Pharmacol 73, 1089-93.PM:24663501
Sonawane, P., Cho, H.E., Tagde, A., Verlekar, D., Yu, A.L., Reynolds,C.P., Kang, M.H. (2014). Metabolic characteristics of 13-cis-retinoic acid (isotretinoin) and anti-tumour activity of the 13-cis-retinoic acidmetabolite 4-oxo-13-cis-retinoic acid in neuroblastoma. Br J Pharmacol 171, 5330-44. PM:25039756
Swartz, D.J., Mok, L., Botta, S.K., Singh, A., Altenberg, G.A., Urbatsch, I.L. (2014). Directed evolution of P-glycoprotein cysteines reveals site-specific, non-conservative substitutions that preserve multidrug resistance. Biosci Rep 34, e00116.
Volk, R.J., McFall, S.L., Cantor, S.B., Byrd, T.L., Le, Y.C., Kuban, D.A.,Mullen, P.D. (2014) . 'It's not like you just had a heart attack': decision-making about active surveillance by men with localized prostate cancer. Psychooncology 23, 467-72.
Youngblood, B.A., MacDonald, C.C. (2014) . CstF-64 is necessary for endoderm differentiation resulting in cardiomyocyte defects. Stem Cell Res 13, 413-21.
Youngblood, B.A., Grozdanov, P.N., MacDonald, C.C. (2014) . CstF-64 supports pluripotency and regulates cell cycle progression in embryonic stem cells through histone 3' end processing. Nucleic Acids Res 42,8330-42.
Youngblood, B.A., Alfano, R., Pettit, S.C., Zhang, D., Dallmann, H.G., Huang, N., MacDonald, C.C. (2014) . Application of recombinant human leukemia inhibitory factor (LIF) produced in rice (Oryza sativa L.) for maintenance of mouse embryonic stem cells. J Biotechnol 20;172:67-72.doi: 10.1016/j.jbiotec.2013.12.012. Epub; 2013 Dec 29., 67-72.
Zoghbi, M.E., Altenberg, G.A. (2014). ATP binding to two sites is necessary for dimerization of nucleotide-binding domains of ABC proteins. Biochem Biophys Res Commun 443, 97-102.

Reynolds CP, Kang MH, Carol H, Lock R, Gorlick R, Kolb EA, Kurmasheva RT, Keir ST, Maris JM, Billups CA, Houghton PJ, Smith MA: Initial testing (stage 1) of the phosphatidylinositol 3' kinase Inhibitor, SAR245408 (XL147) by the Pediatric Preclinical Testing Program. Pediatr Blood Cancer 60:791-798, 2013.
Shibina A, Seidel D, Somanchi S, Lode HN, Lee DA, Reynolds CP, Huebener N: Fenretinide sensitizes multidrug-resistant human neuroblastoma cells to antibody-independent and ch14.18-mediated NK cell cytotoxicity. J Mol Med 91:459-472, 2013.
Sausen M, Leary RJ, Wu J, Reynolds CP, Liu X, Maris J, Blackford A, Parmigiani G, Diaz LA, Papadopoulos N, Vogelstein B, Kinzler KW, Velculescu VE, Hogarty MD: Integrated genomic analyses identify ARID1A and ARID1B alterations in the childhood cancer neuroblastoma. Nature Genetics 45:12-17, 2013.
Keir ST, Maris JM, Reynolds CP, Kang MH, Kolb EA, Gorlick R, Lock R, Carol H, Morton CL, Wu J, Kurmasheva RT, Houghton PJ, Smith MA: Initial testing (stage 1) of temozolomide by the pediatric preclinical testing program. Pediatr Blood Cancer. 60:783-90, 2013. PMID: 23335050
Wood AC, Maris JM, Gorlick R, Kolb EA, Keir ST, Reynolds CP, Kang MH, Wu J, Kurmasheva RT, Whiteman K, Houghton PJ, Smith MA. Initial testing (Stage 1) of the antibody-maytansinoid conjugate, IMGN901 (Lorvotuzumab mertansine), by the pediatric preclinical testing program. Pediatr Blood Cancer. 60:1860-7, 2013. PMID: 23798344
Lock RB, Carol H, Maris JM, Kang MH, Reynolds CP, Kolb EA, Gorlick R, Keir ST, Billups CA, Kurmasheva RT, Houghton PJ, Smith MA. : Initial testing (stage 1) of ganetespib, an Hsp90 inhibitor, by the pediatric preclinical testing program. Pediatr Blood Cancer. 60:E42-5, 2013. PMID: 23303741
Kolb EA, Gorlick R, Reynolds CP, Kang MH, Carol H, Lock R, Keir ST, Maris JM, Billups CA, Desjardins C, Kurmasheva RT, Houghton PJ, Smith MA: Initial testing (stage 1) of eribulin, a novel tubulin binding agent, by the Pediatric Preclinical Testing Program. Pediatr Blood Cancer. 60:1325-32, 2013. PMID 23553917
Maurer BJ, Kang MH, Janeba J, Groshen S, Matthay KK, Sondel PM, Maris JM, Jackson HA, Goodarzian F, Shimada H, Villablanca JG, Czarnecki S, Beth Hasenauer B, Reynolds CP, Marachelian A: Phase I trial of fenretinide delivered orally in a novel organized lipid complex in patients with relapsed neuroblastoma: A report from the NANT consortium. Pediatr Blood Cancer 60:1801-8, 2013. PMID: 23813912
Kreissman SG, Seeger RC, Matthay KK, London WB, Sposto R, Grupp SA, Haas-Kogan DA, M.D., LaQuaglia MP, Yu AL, M.D., Diller L, Buxton A, Park JP, Cohn SL, Maris JM, Reynolds CP, Villablanca JG: Purged versus non-purged peripheral blood stem cell transplant for neuroblastoma. Lancet Oncology 14:999-1008, 2013. PMID: 23890779
Kurmasheva RT, Reynolds CP, Kang MH, Allievi C, Houghton PJ, Smith MA: Initial testing (stage 1) of the topoisomerase II inhibitor pixantrone, by the pediatric preclinical testing program. Pediatr Blood Cancer. 2013 Oct 26. doi: 10.1002/pbc.24800. [Epub ahead of print] PMID: 24166988
Carol H, Gorlick R, Kolb EA, Morton CL, Manesh DM, Keir ST, Reynolds CP, Kang MH, Maris JM, Wozniak A, Hickson I, Lyalin D, Kurmasheva RT, Houghton PJ, Smith MA, Lock R: Initial testing (stage 1) of the histone deacetylase inhibitor, quisinostat (JNJ-26481585), by the Pediatric Preclinical Testing Program. Pediatr Blood Cancer. 2013 Sep 4. doi: 10.1002/pbc.24724. [Epub ahead of print] PMID: 24038993
May, W.A., Grigoryan, R.S., Keshelava, N., Cabral, D.J., Christensen, L.L., Jenabi, J., Ji, L., Triche, T.J., Lawlor, E.R., Reynolds, C.P. (2013). Characterization and drug resistance patterns of Ewing's sarcoma family tumor cell lines. PLoS One 8, e80060. PM:24312454

Kang MH, Reynolds CP, Houghton PJ, Alexander D, Morton CL, Kolb EA, Gorlick R, Keir ST, Carol H, Lock R, Maris JM, Wozniak A, Smith MA: Initial testing (stage 1) of AT13387, an HSP90 inhibitor, by the pediatric preclinical testing program. Pediatr Blood Cancer. 59:185-8, 2012
Houghton PJ, Lock R, Carol H, Morton CL, Gorlick R, Anders Kolb E, Keir ST, Reynolds CP, Kang MH, Maris JM, Billups CA, Zhang MX, Madden SL, Teicher BA, Smith MA: Testing of the topoisomerase 1 inhibitor Genz-644282 by the pediatric preclinical testing program. Pediatr Blood Cancer. 58:200-9, 2012
Lock RB, Carol H, Morton CL, Keir ST, Reynolds CP, Kang MH, Maris JM, Wozniak AW, Gorlick R, Kolb EA, Houghton PJ, Smith MA. Initial testing of the CENP-E inhibitor GSK923295A by the pediatric preclinical testing program. Pediatr Blood Cancer. 58:916-23, 2012
Houghton PJ, Kang MH, Reynolds CP, Morton CL, Kolb EA, Gorlick R, Keir ST, Carol H, Lock R, Maris JM, Billups CA, Smith MA: Initial testing (Stage 1) of LCL161, a SMAC mimetic, by the pediatric preclinical testing program. Pediatr Blood Cancer. 58:636-9, 2012
Smith MA, Gorlick R, Kolb EA, Lock R, Carol H, Maris JM, Keir ST, Morton CL, Reynolds CP, Kang MH, Arts J, Bashir T, Janicot M, Kurmasheva RT, Houghton PJ: Initial testing of JNJ-26854165 (Serdemetan) by the pediatric preclinical testing program. Pediatr Blood Cancer. 59: 329-32, 2012
Gorlick R, Maris JM, Houghton PJ, Lock R, Carol H, Kurmasheva RT, Kolb EA, Keir ST, Reynolds CP, Kang MH, Billups CA, Smith MA: Testing of the Akt/PKB inhibitor MK-2206 by the pediatric preclinical testing program. Pediatr Blood Cancer. 59:518-24, 2012. PMID: 22102563
Batra V, Maris JM, Kang MH, Reynolds CP, Houghton PJ, Alexander D, Kolb EA, Gorlick R, Keir ST, Carol H, Lock R, Billups CA, Smith MA: Initial testing (stage 1) of SGI-1776, a PIM1 kinase inhibitor, by the pediatric preclinical testing program. Pediatr Blood Cancer. 59:749-52, 2012. PMID: 22052829
Kolb EA, Gorlick R, Keir ST, Maris JM, Lock R, Carol H, Kurmasheva RT, Reynolds CP, Kang MH, Wu J, Houghton PJ, Smith MA: Initial testing (stage 1) by the pediatric preclinical testing program of RO4929097, a γ-secretase inhibitor targeting notch signaling. Pediatr Blood Cancer. 58:815-8, 2012. PMID 22052798
Smith MA, Maris JM, Gorlick R, Kolb EA, Lock R, Carol H, Keir ST, Reynolds CP, Kang MH, Morton CL, Wu J, Smith PG, Yu J, Houghton PJ: Initial testing of the investigational NEDD8-activating enzyme inhibitor MLN4924 by the pediatric preclinical testing program. Pediatr Blood Cancer. 59:246-53, 2012. PMID: 22012946
Xu J, Erdreich-Epstein A, Gonzalez-Gomez I, Melendez EY, Smbatyan G, Moats RA, Rosol M, Biegel J, Reynolds CP: Novel cell lines accurately reflect pediatric brain tumors. J Neurooncology 107:269-80, 2012. PMID: 22120608
Gorlick R, Kolb EA, Houghton PJ, Morton CL, Neale G, Keir ST, Carol H, Lock R, Phelps D, Kang MH, Reynolds CP, Maris JM, Billups C, Smith MA: Initial testing (stage 1) of the cyclin dependent kinase inhibitor SCH 727965 (dinaciclib) by the pediatric preclinical testing program. Pediatr Blood Cancer. 59:1266-74, 2012. PMID: 22315240
Smith MA, Kang MH, Reynolds CP, Kurmasheva RT, Alexander D, Billups CA, Toretsky JA, Houghton PJ: Evaluation of arsenic trioxide by the pediatric preclinical testing program with a focus on Ewing sarcoma. Pediatr Blood Cancer. 59:753-5, 2012. PMID: 22315235
Strother DR, London WB, Schmidt ML, Brodeur GM, Shimada H, Thorner P, Collins MH, Tagge E, Adkins S, Reynolds CP, Murray K, Lavey RS, Matthay KK, Castleberry R, Maris JM, Cohn SL: Outcome after surgery alone or with restricted use of chemotherapy for patients with low-risk neuroblastoma: Results of Children's Oncology Group study P9641. J Clin Oncol. 30:1842-8, 2012. PMID: 22529259
Szymanska B, Wilczynska-Kalak U, Kang MH, Liem NL, Carol H, Boehm I, Groepper D, Reynolds CP, Stewart CF, Lock RB: Pharmacokinetic modeling of an induction regimen for in vivo combined testing of novel drugs against pediatric acute lymphoblastic leukemia xenografts. PLoS One. 7:e33894, 2012. PMID: 22479469
Goldsmith KC, Gross M, Peirce S, Luyindula D, Liu X, Vu A, Sliozberg M, Guo R, Zhao H, Reynolds CP, Hogarty MD: Mitochondrial Bcl-2 family dynamics define therapy response and resistance in neuroblastoma. Cancer Res. 72:2565-2577, 2012.
Carol H, Reynolds CP, Kang MH, Keir ST, Maris JM, Gorlick R, Kolb EA, Billups CA, Geier B, Kurmasheva RT, Houghton PJ, Smith MA, Lock RB: Initial testing of the MDM2 inhibitor RG7112 by the pediatric preclinical testing program. Pediatr Blood Cancer. 60:633-41, 2012. PMID: 22753001

JP Cooper, S Bang, H Singh, SC Williams, MH Kang. (2011) Fenretinide cytotoxicity is independent of both constitutive and pharmacologically modulated glutathione levels in pediatric acute lymphoblastic leukemia cells cultured at hypoxia. Pediatric Blood Cancer. (in press).
C Zhang, YK Ryu, TZ Chen, CP Hall, DR Webster, MH Kang. (2011) Synergistic Activity of Rapamycin and Dexamethasone in vitro and in vivo in acute lymphoblastic leukemia via cell-cycle arrest and apoptosis. Leukemia Res. (in press).
Kang MH, Smith MA, Morton CL, Nino Keshelava N, Houghton PJ, Reynolds CP: National Cancer Institute Pediatric Preclinical Testing Program: Model description for in vitro cytotoxicity testing. Pediatr Blood Cancer 56:239-49, 2011.
Houghton PJ, Gorlick R, Kolb EA, Lock R, Carol H, Morton CL, Keir ST, Reynolds CP, Kang MH, Phelps D, Maris JM, Billups C, Smith MA: Initial testing (stage 1) of the mTOR kinase inhibitor AZD8055 by the pediatric preclinical testing program. Pediatr Blood Cancer 58:191-9, 2011
Kolb EA, Gorlick R, Lock R, Carol H, Morton CL, Keir ST, Reynolds CP, Kang MH, Maris JM, Billups C, Smith MA, Houghton PJ: Initial testing (stage 1) of the IGF-1 receptor inhibitor BMS-754807 by the pediatric preclinical testing program. Pediatr Blood Cancer. 56:595-603, 2010
Smith MA, Maris JM, Lock R, Kolb EA, Gorlick R, Keir ST, Carol H, Morton CL, Reynolds CP, Kang MH, Houghton PJ: Initial Testing (Stage 1) of the polyamine analog PG11047 by the Pediatric Preclinical Testing Program Pediatr Blood Cancer 57:268-74, 2011.
Reynolds CP, Kang MH, Keir ST, Gorlick R, Kolb EA, Lock R, Maris JM, Carol H, Morton CL, Billups CA, MS, Smith MA, MD, Houghton PJ: Initial testing of lenalidomide by the Pediatric Preclinical Testing Program. Pediatr Blood Cancer 57:606-11, 2011.
Cooper J, Kyunghwa H, Hardeep S, Wang, D, Reynolds CP, Robert C, Simon W, Maurer BJ, Kang MH: Fenretinide metabolism in humans and mice: Utilizing pharmacologic modulation of its metabolic pathway to increase systemic exposure. British J Pharmacology 163:1263-75, 2011.
Carol H, Boehm I, Reynolds CP, Kang MH, Maris JM, Morton CL, Gorlick R, Kolb EA, Keir ST, Wu J, Wozniak AE, Yang Y, Manfredi M, Ecsedy J, Wang J, Neale G, Houghton PJ, Smith MA, Lock RB: Efficacy and pharmacokinetic/pharmacodynamic evaluation of the Aurora kinase A inhibitor MLN8237 against preclinical models of pediatric cancer. Cancer Chemother Pharmacol. 68:1291-304, 2011
Kummar S, Gutierrez ME, Maurer BJ, Reynolds CP, Kang M, Singh H, Crandon S, Murgo AJ, Doroshow JH: Phase I trial of fenretinide Lym-X-sorb oral powder in adults with solid tumors and lymphomas. Anticancer Res. 31:961-6, 2011.
Fang H, Harned TM, Kalous O, Maldonado V, DeClerck YA, Reynolds CP: Synergistic activity of fenretinide and the Bcl-2 family protein inhibitor ABT-737 against human neuroblastoma. Clinical Cancer Research 17:7093-104, 2011.
Villablanca JG, London WB, Naranjo A, McGrady MS, Ames MM, Joel M. Reid JM, McGovern RM, Buhrow SA, Stranzinger JH, Kitchen BJ, Sondel PM, Parisi M, Shulkin B, Yanik GA, Cohn S, Reynolds CP: Phase II study of oral capsular 4-hydroxyphenylretinamide (4-HPR/fenretinide) in pediatric patients with refractory or recurrent neuroblastoma: A report from the Children's Oncology Group NSC #374551; IND# 40294. Clinical Cancer Research 17:6858-6866, 2011.

Smith MA, Morton CL,: Kolb, EA, Gorlick, R, Keir ST, Carol H, Lock RB, Kang MH, Reynolds CP, MD, Maris JM, Watkins AE, Houghton PJ: Initial testing (Stage 1) of mapatumumab (HGS-ETR1) by the Pediatric Preclinical Testing Program. Pediatr Blood Cancer 54:307-10, 2010.
Houghton PJ, Morton CL, Gorlick R, Lock RB, Carol H, Reynolds CP, Kang MH, Maris JM, Keir ST, Kolb EA, Wu J, Wozniak AW, Billups CA, Rubinstein L, Smith MA: Stage 2 combination testing of rapamycin with cytotoxic agents by the Pediatric Preclinical Testing Program. Mol Cancer Therapeutics 9:101-12, 2010.
Hazen RA, Eder M, Ph.D., Drotar D, Zyzanski S, Reynolds AE, M.F.A, Reynolds CP, Kodish E, Noll RB: A feasibility trial of a video intervention to improve informed consent for parents of children with leukemia Pediatr Blood Cancer 55:113-8, 2010.
Horton TM, Sposto R, Brown P, Reynolds CP, Hunger SP, Winick N, Raetz E, William Carroll W, Arceci A, Borowitz M, Gaynon P, Gore L, Jeha S, Maurer B, Siegel SE, Biondi A, Kearns P, Narendran A, Silverman L, Smith M, Zwaan M, Whitlock J: Toxicity assessment of new agents incorporated into induction regimens for pediatric acute lymphocytic leukemia (ALL): Results of an international consensus conference. Pediatr Blood Cancer 54:872-878, 2010.
Kang HG, Jenabi JM, Liu XF, Reynolds CP, Triche TJ, Sorensen PH: Inhibition of the insulin-like growth factor I receptor by epigallocatechin gallate blocks proliferation and induces the death of Ewing tumor cells. Mol Cancer Therapeutics 9:1396-407, 2010.
Maris JM, Morton CL, Gorlick R, Kolb EA, Lock R, Carol H, Keir ST, Reynolds CP, Kang MH, Wu J, Smith MA, Houghton PJ: Initial testing of the aurora kinase A inhibitor MLN8237 by the Pediatric Preclinical Testing Program (PPTP). Pediatr Blood Cancer. 55:26-34, 2010.
Houghton PJ, Morton CL, Gorlick R, Kolb EA, Keir ST, Reynolds CP, Kang MH, Maris JM, Wu J, Smith MA: Initial testing of a monoclonal antibody (IMC-A12) against IGF-1R by the pediatric preclinical testing program. Pediatr Blood Cancer 54:921-6, 2010.
Lee J, Singh H, Maurer BJ, Reynolds CP, Kang MH: A validated LC with fluorescence detection method for simultaneous determination of safingol and D-erythro-sphinganine in human plasma. Chromatographia 71:1087-1091 2010.
Morton CL, Houghton PJ, Kolb EA, Gorlick R, Reynolds CP, Kang MH, Maris JM, Keir ST, Wu J, Smith MA: Initial testing of the replication competent Seneca Valley virus (NTX-010) by the pediatric preclinical testing program. Pediatr Blood Cancer. 55:295-303, 2010.
Kolb EA, Gorlick R, Houghton PJ, Morton CL, Neale G, Keir ST, Carol H, Lock R, Phelps D, Kang MH, Reynolds CP, Maris JM, Billups C, Smith MA: Initial testing (stage 1) of AZD6244 (ARRY-142886) by the pediatric preclinical testing program. Pediatr Blood Cancer. 55:668-77,2010.
Yu AL, Gilman AL, Ozkaynak MF, London WB, Kreissman SG, Chen HX, Smith M, Anderson B, Villablanca JG, Matthay KK, Shimada H, Grupp SA, Seeger RC, Reynolds CP, Buxton A, Reisfeld RA, Gillies SD, Cohn SL, Maris JM, Sondel PM: Anti-GD2 antibody with GM-CSF, IL2 and isotretinoin for neuroblastoma: A Children's Oncology Group (COG) Phase III Study. New England J Medicine 363:22-32, 2010.
Baker DL, Schmidt ML, Cohn SL, Maris JM, London WB, Buxton A, Stram D, Castleberry RP, Shimada S, Sandler A, Shamberger RC, Look AT, Reynolds CP, Seeger RC, Matthay KK: Outcome after reduced chemotherapy for intermediate-risk neuroblastoma. New England J Medicine 363:1313-1323, 2010.
Houghton PJ, Morton CL, Kang MH, Reynolds CP, Billups CA, Favours E, Payne-Turner D, Tucker C, Smith MA: Evaluation of cytarabine against Ewing sarcoma xenografts by the Pediatric Preclinical Testing Program. Pediatr Blood Cancer 55:1224-6, 2010.
Shusterman SS, London WB, Gillies SD, Hank JA, Voss SD, Seeger RC, Reynolds CP, Kimball J, Albertini MRA, Wagner B, Gan J, Eickhoff J, De Santes KB, Cohn SL, Hecht T, Gadbaw B, Reisfeld RA, Maris JM, and Sondel PM: Anti-tumor activity of hu14.18-IL2 (EMD 273063) in relapsed/refractory neuroblastoma patients: a Children's Oncology Group (COG) phase II study. J Clinical Oncology 28:4969-75, 2010.
Cai, W, Maldonado V, Ji L, Sposto R, Reynolds CP, Keshelava N: Activity of irinotecan and temozolomide in the presence of O⁶-methylguanine-DNA methyltransferase inhibition in neuroblastoma pre-clinical models. Br J Cancer 103:1369-1379, 2010.
Keir ST, Maris JM, Lock R, Kolb EA, Gorlick R, Carol H, Morton CL, Reynolds CP, Kang MH, Watkins A, Houghton PJ, Smith MA: Initial testing (stage 1) of the multi-targeted kinase inhibitor sorafenib by the pediatric preclinical testing program. Pediatr Blood Cancer 55:1126-33, 2010.
Hadjidaniel MD and Reynolds CP: Antagonism of cytotoxic chemotherapy in neuroblastoma cell lines by retinoic acid is mediated by the anti-apoptotic Bcl-2 family proteins. Mol Cancer Therapeutics 9:3164-74, 2010.
Kapranov P, St. Laurent G, Raz T, Fatih Ozsolak F, Reynolds CP, Sorensen PHB, Reaman G, Milos P, Arceci RJ, Thompson JF, Triche TJ: The majority of total nuclear-encoded non-ribosomal RNA in a human cell is "dark matter" unannotated RNA BMC Biology 8:149 [Epub] 2010
Carol H, Morton CL, Gorlick R, Kolb EA, Keir ST, Reynolds CP, Kang MH, Maris JM, Billups C, Smith MA, Houghton PJ, Lock RB: Initial testing (stage 1) of the Akt inhibitor GSK690693 by the pediatric preclinical testing program. Pediatr Blood Cancer 55:1329-37, 2010.
Houghton PJ, Lock R, Carol H, Morton CL, Phelps D, Gorlick R, Kolb EA, Keir ST, Reynolds CP, Kang MH, Maris JM, Wozniak AW, Gu Y, Wilson WR, Smith MA: Initial testing of the hypoxia-activated prodrug PR-104 by the pediatric preclinical testing program Pediatr Blood Cancer. 2010 Dec 27. [Epub]

MH Kang^†, N Harutyunyan, CP Hall, RA Papa, RB Lock. (2009). In vitro and in vivo Activity of Methotrexate and Aminopterin against acute lymphoblastic leukemia and lymphoma. Br. J. Haematol. 145, 389-393.
Kang MH, , Reynolds CP. Bcl-2 inhibitors: Targeting mitochondrial apoptotic pathways in cancertherapy. . Clinical Cancer Research . 2009;15:1126-1132.

Home

Give

Give

Helpful Links

Got Questions?

Spotlight Example Header